Advances in Cancer Chemotherapy

  • Emil FreiIII


Like all therapeutics, cancer chemotherapy began as a largely emperical effort with a major emphasis on the interplay between serendipity and screening. The first major point I would like to make in this presentation is that a scientific base for cancer chemotherapy and for the construction of clinical trials has developed rapidly in the past five to 15 years. Basic research on the nature of the neoplastic cell has provided an increasing number of leads with respect to therapeutic targets exploitable by chemotherapy and immunotherapy (Fig. 1). The sciences of pharmacology and its subsets and of cytokinetics and biostatistics, uhich some refer to as “bridging sciences”, now impinge daily and importantly on the development and application of chemotherapeutic programs to man (Fig. 1). I would like to cite one important recent example that relates to structure activity studies.


Osteogenic Sarcoma Combination Chemotherapy Complete Remission Rate Embryonal Rhabdomyosarcoma Overt Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Di Marco, A., & Lenaz, L. Daunomycin and Adriamycin. In Cancer Medicine, Eds. J.F. Holland and E. Frei III, Lea & Febiger, Philadelphia, 1973, pp. 826–835.Google Scholar
  2. 2.
    Blum, R.H. & Carter S.K. A new cancer drug with significant clinical activity. Ann. Internal Med. 80, 249–259, 1974.Google Scholar
  3. 3.
    Pigram, W.J., Fuller, W. & Hamilton, L.D. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nature New Biol. 235: 17–19, 1972.PubMedCrossRefGoogle Scholar
  4. 4.
    Skipper, H.E., Schabel, F.M. Jr. Quantitative and cytokinetic studies in experimental tumor models. In Cancer Medicine, Eds. J.F. Holland, E. Frei III, Lea & Febiger, Philadelphia, 1973, pp. 629–650.Google Scholar
  5. 5.
    Hakala, M.T. Transport of antineoplastic agents. In Antineoplastic and Immunosuppressive Agents. Chapter 13, pp. 240–269, 1974.Google Scholar
  6. 6.
    Tannock, I.F. The relation between cell proliferation and the vascular system in transplanted mouse mammary tumour. Brit. J. Cancer, 22: 258–273, 1968.PubMedCrossRefGoogle Scholar
  7. 7.
    Djerassi, I., Rominger, C. J. Kim, J.S. et al. Phase I study of high doses of methotrexate with citrovorum factor in patients uith lung cancer. Cancer 30:22–30, 1972.PubMedCrossRefGoogle Scholar
  8. 8.
    Jaffe, N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30:1627–1631, 1972.PubMedCrossRefGoogle Scholar
  9. 9.
    Cortes, E.P., Holland, J.F., Wang, J.J. et al. Doxorubicin in disseminated osteosarcoma. JAMA 221:1132–1138, 1972.CrossRefGoogle Scholar
  10. 10.
    Frei, E III, Jaffe, N, Tattersall, M.H.N., Pitman, S. New approaches to cancer chemotherapy with methotrexate. New Engl. J. Med. 292: 846–851, April 17, 1975.PubMedCrossRefGoogle Scholar
  11. 11.
    Fisher, B., Carbone, P., Economou, S.G. et al. l-Phen-ylalanine mustard (L-PAM) in the management of breast cancer: A report of early findings. New Engl. J. Med. 292:117–122, 1975.PubMedCrossRefGoogle Scholar
  12. 12.
    Canellos, G.P., Taylor, S.G. III., Band, P. & Pocock, S. Combination chemotherapy for advanced breast cancer: randomized comparison with single drug therapy. Prox. XI Intern. Cancer Congress 3:596, 1974 (abstr.)Google Scholar
  13. 13.
    Frei, E. III. Combination cancer therapy: Presidential address. Cancer Research Vol 32:2593–2607, 1972.PubMedGoogle Scholar
  14. 14.
    Sartorelli, A.C. Combination chemotherapy. Cancer Medicine, Eds. J.F. Holland and E. Frei III, Lea & Febiger, Philadelphia, 1973, pp. 706–716, 1973.Google Scholar
  15. 15.
    Easson, E.C. & Russel, M.H. The cure of Hodgkin’s disease. Brit. J. Med. 1:1704–1707, 1963.CrossRefGoogle Scholar
  16. 16.
    DeVita, V.T. Jr., Canellos, G.P., Chabner, B. et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy. Lancet 1:248–250, 1975.PubMedCrossRefGoogle Scholar
  17. 17.
    Skarin, A., Rosenthal, D., Moloney, W. & Frei, E.III. Treatment of advanced non-Hodgkin’s lymphoma (NHL) with bleomycin (B), adriamycin (A), cyclophosphamide (C) and vincristine (O) and prednisone (P)(BAC0P), AACR/ASCO Proceedings 15:133, 1974.Google Scholar
  18. 18.
    Gottlieb, J., Baker, L.H., O’Brien, R.M. et al. Adriamycin used alone and in combination in soft tissue and bone sarcomas. Cancer Chemotherapy Reports (In press).Google Scholar
  19. 19.
    Frei, E. III & Freireich, E.J. Progress and perspective in the chemotherapy of acute leukemia. Advances Chemother. 2:269, 1965.Google Scholar
  20. 20.
    Ansfield, F.J. A randomized phase III study of four dosaoes reoimens of 5-fluorouracil — A preliminary report. 11th Annual Meeting of the American Society of Clinical Oncology, Abstract 1014, p. 224, 1975.Google Scholar
  21. 21.
    Sallan, S., Zinberg, N., Frei, E, III. Oral delta-9-tetrahydrocannabinol (THC) in the prevention of vomiting (V) associated with cancer chemotherapy (CC) 66th Annual Meeting of the American Association for Cancer Research, Abstract 575, p. 144, 1975.Google Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Emil FreiIII
    • 1
  1. 1.Sidney Farber Cancer CenterBostonUSA

Personalised recommendations